STAT48%
Roche 13%
By Meghana Keshavan0% John Wilkerson72% https:46% www.statnews.com49% #43% schema42% person43% 43d3754d214b1b11fc018c1f68d205280% ef9dff1e40397b455feeda01bf5b01f30%
7/10/2026, 1:35:37 PM
BS Summary: This article contains 1 faulty reasoning type, including Attempt to Sell a Product or Service, with Attempt to Sell a Product or Service as the most egregious example at 11.7% saturation with 37 hits. Analysis detected 37 faulty-reasoning hits from 315 analyzed words, generating a BS Score of 30% and a BS Rank of 13% (12,813 of 14,612 articles). This article is better (less manipulative) than 87.70% of the article peer group.
Newsletter The Readout
Roche ends Huntington’s gene-silencing programs
ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout
SEBASTIEN BOZON/AFP via Getty Images
By Meghana Keshavan and John Wilkerson
Meghana Keshavan covers biotech and contributes to The Readout newsletter .
John writes about the politics of health care, and he is the author of the twice-weekly D.C.
Diagnosis newsletter .
You can reach John on Signal at John_Wilkerson.07.
Want to stay on top of the science and politics driving biotech today?
Sign up to get our biotech newsletter in your inbox.
ARPA-H has unveiled a $160 million effort to speed bespoke gene-editing therapies for rare diseases into the clinic.
Meanwhile, Roche has abandoned two Huntington’s gene-silencing drugs after disappointing data, and drugmakers have stepped in to promote Medicare’s new obesity drug discount program.
I got coffee with my cousin this morning here in SF.
Before leaving for his job at an AI behemoth, he said the bone-chilling July gloom is perfect “working weather.”
STAT+ Exclusive Story
Already have an account?
Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Totals $468 per year
for 3 months, then $399/year
Savings start at 25%!
$300 Annually per user
To read the rest of this story subscribe to STAT+.
biotechnology , drug development , Drug prices , research
Submit a correction request Reprints
Biotech Correspondent
Washington Correspondent
STAT Plus: ARPA-H launches $160 million effort to develop custom gene editing drugs
STAT Plus: Prime wins Beam arbitration, clearing path to clinic
Adam's Biotech Scorecard
STAT Plus: 931 days.
The drug approval scandal hiding in plain sight
STAT Plus: AstraZeneca, Ionis report major trial failure with heart disease drug
STAT Plus: The quest to save Grace — and clear the way for rare disease patients everywhere
Speakers
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.